Skip to main content

Rheumatoid Arthritis

      2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia

      A collaborative EULAR/ACR expert panel has establis

      Dr. John Cush RheumNow

      4 months 1 week ago
      2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA). Risk stratification of CSA https://t.co/STmuNO3c2Z
      In the United States, IL-6R inhibitors have continued to help PMR patients get off steroids.

      Hopefully more use and mor

      David Liew drdavidliew

      4 months 1 week ago
      In the United States, IL-6R inhibitors have continued to help PMR patients get off steroids. Hopefully more use and more options mean that, in the future, PMR patients get no more steroids than PsA or RA patients #EULAR2025 POS0948 @RheumNow https://t.co/JT7gFDC5rl
      -Difficult to treat RA is a heterogeneous concept
      -Risk fx: younger onset, high disease activity,erosive disease, comorb

      Adela Castro AdelaCastro222

      4 months 1 week ago
      -Difficult to treat RA is a heterogeneous concept -Risk fx: younger onset, high disease activity,erosive disease, comorbidities, depression. -Study in a Spanish cohort with D2T 2/2 inefficacy showed Rituximab, JAKis, and IL-6i had longer survival (hence better tx options). -The https://t.co/ZCZcX9FRfb
      In BIODOPT study (RA, PsA, axSpA), disease activity-guided tapering of biologics (incl. biosimilars) maintained QALY (Δ

      Antoni Chan MD (Prof) synovialjoints

      4 months 1 week ago
      In BIODOPT study (RA, PsA, axSpA), disease activity-guided tapering of biologics (incl. biosimilars) maintained QALY (Δ0.008, NS) while lowering biologic costs (Δ€–1,979 [95%CI –3,798;–161]) & total hospital costs (Δ€–1,936 [95%CI –3,753;–119]) over 18mo. Supports https://t.co/CJUpfU2oRA
      Late-Onset Disease: Different Age, Different Rules?

      We’re seeing more patients develop rheumatic diseases for the fi

      Dr. John Cush RheumNow

      4 months 1 week ago
      Late-Onset Disease: Different Age, Different Rules? We’re seeing more patients develop rheumatic diseases for the first time in their 60s, 70s, or beyond. But are these truly the same diseases we see in younger adults, or do they behave differently, shaped by age-related https://t.co/ubVRhhRGxG
      #EULAR vs #ACR #RA #recommendations
      Do you agree that #ERA pts should receive #glucocorticoids

      @RheumNow #EULAR2025
      @e

      Janet Pope Janetbirdope

      4 months 1 week ago
      #EULAR vs #ACR #RA #recommendations Do you agree that #ERA pts should receive #glucocorticoids @RheumNow #EULAR2025 @eular_org
      ARIAA study: longer-term data now

      High-risk ACPA+ clinically suspect arthralgias
      abatacept for 6mo, then stop altogethe

      David Liew drdavidliew

      4 months 1 week ago
      ARIAA study: longer-term data now High-risk ACPA+ clinically suspect arthralgias abatacept for 6mo, then stop altogether Really impressive long-term effect also noting success of APIPPRA, abatacept flicks off some very early RA, at least for a while #EULAR2025 OP0325 @RheumNow https://t.co/AeRrUKPPiK https://t.co/jtynyD0ioO
      Highlights @eular_org #EULAR2025
      RCTs + in CTD/RA #ILD w #PPF LB0003

      Lots of #CAR-T studies in #SARDs

      Lots of bDMARDs

      Janet Pope Janetbirdope

      4 months 1 week ago
      Highlights @eular_org #EULAR2025 RCTs + in CTD/RA #ILD w #PPF LB0003 Lots of #CAR-T studies in #SARDs Lots of bDMARDs in #SLE #APS #IgG4 #SjD Neurostimulation 👇 ⬇️inflammation ⬇️pain #RA #fibromyalgia #EULAR2025 @RheumNow @eular_org
      Why do we need RA treatment recommendation updates? We keep on getting new data, for our keystone disease

      so today Jose

      David Liew drdavidliew

      4 months 1 week ago
      Why do we need RA treatment recommendation updates? We keep on getting new data, for our keystone disease so today Josef Smolen and colleagues present the new 2025 EULAR recommendations #EULAR2025 @RheumNow https://t.co/OdHL8CAIKv
      67% of HCPs knew of EULAR’s CVD risk guidelines in RMDs—but few could apply them.
      ✅ Only 13% linked SLE control to

      Jiha Lee JihaRheum

      4 months 1 week ago
      67% of HCPs knew of EULAR’s CVD risk guidelines in RMDs—but few could apply them. ✅ Only 13% linked SLE control to CVD risk 🚫 0% picked correct BP/statin use in RA/AS/PsA Barriers? Time, knowledge, and local guideline gaps. POS0410-HPR @RheumNow #EULAR2025
      “That is why this task force continues to say: nothing is better than methotrexate and glucocorticoids to start”

      -

      David Liew drdavidliew

      4 months 1 week ago
      “That is why this task force continues to say: nothing is better than methotrexate and glucocorticoids to start” - Josef Smolen, on RA treatment #EULAR2025 @RheumNow https://t.co/AbkgWS8tvH
      #EULAR new #RA #recommendations

      J Smolen presents justification for
      #MTX +#glucocorticoids at onset

      do you agree?

      D

      Janet Pope Janetbirdope

      4 months 1 week ago
      #EULAR new #RA #recommendations J Smolen presents justification for #MTX +#glucocorticoids at onset do you agree? Diff from #ACR #EULAR #Recommendations II #EULAR2025 @RheumNow https://t.co/wqCX5HA87q
      #EULAR2025 @eular_org update

      #Recommendations #Rheumatoid #Rx

      prof Smolen
      subtle diff between former guidelines

      MTX

      Janet Pope Janetbirdope

      4 months 1 week ago
      #EULAR2025 @eular_org update #Recommendations #Rheumatoid #Rx prof Smolen subtle diff between former guidelines MTX+GC 👇 D/C GCs rapidly 👇 If inadequate response 👇 Other csDMARDs are OUT ❎ ✅go to bDMARD or tsDMARD* TsDMARD after safety assessed @RheumNow RecommendatnII https://t.co/yUrLdk6Eg1
      ×